Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children

A report from the Childrens Cancer Study Group

A. T. Meadows, R. Sposto, R. D.T. Jenkin, J. H. Kersey, R. R. Chilcote, S. E. Siegel, Peter Felix Coccia, J. Rosenstock, K. C. Pringle, C. J. Stolar, M. E. Kadin, G. D. Hammond

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Successful treatment of localized non-Hodgkin's lymphoma (NHL) in childhood with 18 months of cyclophosphamide, vincristine, methotrexane (MTX), and prednisone (COMP) prompted a randomized clinical trial to determine whether a 6-month course of the same therapy was as effective as an 18-month course when combined with local irradiation. Two successive Childrens Cancer Study Group (CCSG) protocols (CCG 551 and CCG 501) entered 232 eligible patients from October 1979 until April 1986. Initially, all children with localized disease were considered eligible, but by a subsequent amendment, those with lymphoblastic (LB) histology were excluded. Hence, the study population consisted of 211 patients with nonlymphoblastic (NLB) and 21 with LB disease. Early relapses (before 6 months) occurred in 13 patients with NLB histology. Late relapses were seen in seven patients, three with LB histology. Among the 104 randomized patients who followed the prescribed therapy, there were four recurrences and no differences between 6-month and 18-month therapy. The overall survival for NLB disease was 91% on CCG 551 and 98% on CCG 501. We conclude that 6 months of COMP is excellent therapy for children with localized NLB NHL.

Original languageEnglish (US)
Pages (from-to)92-99
Number of pages8
JournalJournal of Clinical Oncology
Volume7
Issue number1
DOIs
StatePublished - Jan 1 1989

Fingerprint

Non-Hodgkin's Lymphoma
Histology
Pharmaceutical Preparations
Neoplasms
Recurrence
Therapeutics
Vincristine
Prednisone
Cyclophosphamide
Randomized Controlled Trials
Survival
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children : A report from the Childrens Cancer Study Group. / Meadows, A. T.; Sposto, R.; Jenkin, R. D.T.; Kersey, J. H.; Chilcote, R. R.; Siegel, S. E.; Coccia, Peter Felix; Rosenstock, J.; Pringle, K. C.; Stolar, C. J.; Kadin, M. E.; Hammond, G. D.

In: Journal of Clinical Oncology, Vol. 7, No. 1, 01.01.1989, p. 92-99.

Research output: Contribution to journalArticle

Meadows, AT, Sposto, R, Jenkin, RDT, Kersey, JH, Chilcote, RR, Siegel, SE, Coccia, PF, Rosenstock, J, Pringle, KC, Stolar, CJ, Kadin, ME & Hammond, GD 1989, 'Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children: A report from the Childrens Cancer Study Group', Journal of Clinical Oncology, vol. 7, no. 1, pp. 92-99. https://doi.org/10.1200/JCO.1989.7.1.92
Meadows, A. T. ; Sposto, R. ; Jenkin, R. D.T. ; Kersey, J. H. ; Chilcote, R. R. ; Siegel, S. E. ; Coccia, Peter Felix ; Rosenstock, J. ; Pringle, K. C. ; Stolar, C. J. ; Kadin, M. E. ; Hammond, G. D. / Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children : A report from the Childrens Cancer Study Group. In: Journal of Clinical Oncology. 1989 ; Vol. 7, No. 1. pp. 92-99.
@article{cabf7ee029624cbab3639430a55c89bd,
title = "Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children: A report from the Childrens Cancer Study Group",
abstract = "Successful treatment of localized non-Hodgkin's lymphoma (NHL) in childhood with 18 months of cyclophosphamide, vincristine, methotrexane (MTX), and prednisone (COMP) prompted a randomized clinical trial to determine whether a 6-month course of the same therapy was as effective as an 18-month course when combined with local irradiation. Two successive Childrens Cancer Study Group (CCSG) protocols (CCG 551 and CCG 501) entered 232 eligible patients from October 1979 until April 1986. Initially, all children with localized disease were considered eligible, but by a subsequent amendment, those with lymphoblastic (LB) histology were excluded. Hence, the study population consisted of 211 patients with nonlymphoblastic (NLB) and 21 with LB disease. Early relapses (before 6 months) occurred in 13 patients with NLB histology. Late relapses were seen in seven patients, three with LB histology. Among the 104 randomized patients who followed the prescribed therapy, there were four recurrences and no differences between 6-month and 18-month therapy. The overall survival for NLB disease was 91{\%} on CCG 551 and 98{\%} on CCG 501. We conclude that 6 months of COMP is excellent therapy for children with localized NLB NHL.",
author = "Meadows, {A. T.} and R. Sposto and Jenkin, {R. D.T.} and Kersey, {J. H.} and Chilcote, {R. R.} and Siegel, {S. E.} and Coccia, {Peter Felix} and J. Rosenstock and Pringle, {K. C.} and Stolar, {C. J.} and Kadin, {M. E.} and Hammond, {G. D.}",
year = "1989",
month = "1",
day = "1",
doi = "10.1200/JCO.1989.7.1.92",
language = "English (US)",
volume = "7",
pages = "92--99",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children

T2 - A report from the Childrens Cancer Study Group

AU - Meadows, A. T.

AU - Sposto, R.

AU - Jenkin, R. D.T.

AU - Kersey, J. H.

AU - Chilcote, R. R.

AU - Siegel, S. E.

AU - Coccia, Peter Felix

AU - Rosenstock, J.

AU - Pringle, K. C.

AU - Stolar, C. J.

AU - Kadin, M. E.

AU - Hammond, G. D.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Successful treatment of localized non-Hodgkin's lymphoma (NHL) in childhood with 18 months of cyclophosphamide, vincristine, methotrexane (MTX), and prednisone (COMP) prompted a randomized clinical trial to determine whether a 6-month course of the same therapy was as effective as an 18-month course when combined with local irradiation. Two successive Childrens Cancer Study Group (CCSG) protocols (CCG 551 and CCG 501) entered 232 eligible patients from October 1979 until April 1986. Initially, all children with localized disease were considered eligible, but by a subsequent amendment, those with lymphoblastic (LB) histology were excluded. Hence, the study population consisted of 211 patients with nonlymphoblastic (NLB) and 21 with LB disease. Early relapses (before 6 months) occurred in 13 patients with NLB histology. Late relapses were seen in seven patients, three with LB histology. Among the 104 randomized patients who followed the prescribed therapy, there were four recurrences and no differences between 6-month and 18-month therapy. The overall survival for NLB disease was 91% on CCG 551 and 98% on CCG 501. We conclude that 6 months of COMP is excellent therapy for children with localized NLB NHL.

AB - Successful treatment of localized non-Hodgkin's lymphoma (NHL) in childhood with 18 months of cyclophosphamide, vincristine, methotrexane (MTX), and prednisone (COMP) prompted a randomized clinical trial to determine whether a 6-month course of the same therapy was as effective as an 18-month course when combined with local irradiation. Two successive Childrens Cancer Study Group (CCSG) protocols (CCG 551 and CCG 501) entered 232 eligible patients from October 1979 until April 1986. Initially, all children with localized disease were considered eligible, but by a subsequent amendment, those with lymphoblastic (LB) histology were excluded. Hence, the study population consisted of 211 patients with nonlymphoblastic (NLB) and 21 with LB disease. Early relapses (before 6 months) occurred in 13 patients with NLB histology. Late relapses were seen in seven patients, three with LB histology. Among the 104 randomized patients who followed the prescribed therapy, there were four recurrences and no differences between 6-month and 18-month therapy. The overall survival for NLB disease was 91% on CCG 551 and 98% on CCG 501. We conclude that 6 months of COMP is excellent therapy for children with localized NLB NHL.

UR - http://www.scopus.com/inward/record.url?scp=0024601087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024601087&partnerID=8YFLogxK

U2 - 10.1200/JCO.1989.7.1.92

DO - 10.1200/JCO.1989.7.1.92

M3 - Article

VL - 7

SP - 92

EP - 99

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -